Revance Earnings Reports

Revance reported an 11% increase in total net revenue for the third quarter, reaching $59.9 million compared to $54.1 million for the same period in 2023. This growth was primarily driven by increased sales volume of DAXXIFY and the RHA® Collection, although partially offset by reduced average selling prices for both product lines. The company is withdrawing its 2024 financial guidance due to a proposed merger with Crown.

Revance reported a 20% increase in total net revenue for Q2 2024, driven by growth in DAXXIFY and RHA Collection sales. The company launched DAXXIFY for cervical dystonia and reiterated its 2024 total net product revenue guidance of at least $280 million.

Revance Therapeutics reported a total net revenue of $51.9 million for Q1 2024, a 13% increase compared to the same period last year, driven by increased DAXXIFY sales. The company is on track to generate combined sales of DAXXIFY and the RHA Collection of at least $280 million in 2024.

Revance reported a strong fourth quarter and full year 2023, with total revenue reaching $69.8 million for the quarter, a 40% increase year-over-year. Product revenue for the quarter was $58.5 million, driven by sales of DAXXIFY and the RHA Collection. The company is on track to launch DAXXIFY for cervical dystonia in mid-2024 and anticipates achieving positive Adjusted EBITDA in 2025.

Revance reported a near doubling of total revenue to $56.8 million compared to the same period last year, driven by the commercialization of DAXXIFY and sales growth of the RHA Collection. The company is focusing on capital allocation priorities and expects to reach positive Adjusted EBITDA in 2025.

Revance reported a strong second quarter with total revenue of $58.1 million, a 104.9% increase year-over-year. The growth was driven by the sales of the RHA® Collection and the commercialization of DAXXIFY®. The company bolstered its financial position with $100 million net proceeds from its ATM program and has $50 million in notes available through Athyrium Capital.

Revance reported strong Q1 2023 results with a 95.3% YoY increase in total revenue, driven by the growth of the RHA® Collection of dermal fillers and the successful launch of DAXXIFY®.

Revance Therapeutics reported a strong Q4 2022, with total revenue reaching $49.9 million, a 92% increase year-over-year. The company saw significant growth in RHA® Collection revenue and initial revenue from DAXXIFY® during the PrevU program. The company is preparing for the commercial launch of DAXXIFY® in late March 2023.

Revance Therapeutics reported strong Q3 2022 financial results, highlighted by FDA approval of DAXXIFY™ and a 47% year-over-year increase in total revenue. The company also completed a $230 million follow-on offering, strengthening its financial position.

Revance Therapeutics reported a strong second quarter, with revenue of $28.4 million, a 51% increase from the same period in 2021. The company's RHA® Collection revenue reached $25.5 million, marking its best performing quarter since launch.

Revance Therapeutics reported an 89.9% increase in first-quarter revenue to $25.3 million, driven by a 78.9% increase in RHA® Collection revenue to $20.8 million. The company also closed a $300 million note purchase agreement and raised $31.8 million in net proceeds through its ATM program. The PDUFA date for DaxibotulinumtoxinA for Injection for glabellar lines is set for September 8, 2022.

Revance Therapeutics reported Q4 2021 revenue of $26.0 million, compared to $11.1 million for the same period in 2020. The net loss for the quarter was $63.1 million, compared to a net loss of $78.3 million for the same period in 2020. The company had cash, cash equivalents and short-term investments of $225.1 million as of December 31, 2021.

Revance Therapeutics reported strong revenue growth in Q3 2021, driven primarily by increased sales of the RHA® Collection of dermal fillers. The company is engaging with the FDA to address deficiencies related to the BLA for DaxibotulinumtoxinA for Injection and focusing on strategic priorities including growing dermal filler revenue and expanding customer relationships through OPUL™.

Revance Therapeutics reported a strong second quarter with revenue totaling $18.8 million, driven by $17.0 million in RHA® Collection sales and increased fintech payment processing volume.

Revance Therapeutics reported strong commercial execution in Q1 2021, with revenue totaling $13.3 million, primarily driven by sales of the RHA® Collection of dermal fillers and increased revenue from the biosimilar program. The company is progressing with its therapeutics franchise and anticipates FDA approval for DaxibotulinumtoxinA for Injection this year.

Revance Therapeutics, Inc. reported strong fourth-quarter results, driven by the commercial launch of the RHA® Collection of dermal fillers and the HintMD fintech platform. The company's revenue increased significantly compared to the same period in 2019, and they exited 2020 with a substantial cash balance, positioning them for continued growth and pipeline advancement.

Revance Therapeutics reported financial results for Q3 2020. The company's first commercial quarter, marked by the launch of the Prestige Aesthetics Portfolio, generated $3.0 million in revenues. Positive Phase 3 results were announced from the ASPEN-1 study in cervical dystonia.

Revance reported revenue of $0.3 million for Q2 2020. The company is focused on the commercial launch of RHA® Collection of Dermal Fillers and the HintMD fintech platform, and anticipates potential U.S. regulatory approval of DaxibotulinumtoxinA for Injection in glabellar lines in November.

Revance Therapeutics reported financial results for the quarter ended March 31, 2020. Key updates included the FDA acceptance of the BLA for DaxibotulinumtoxinA for Injection in Glabellar Lines, the signing of an exclusive U.S. distribution agreement for TEOXANE Dermal Fillers, and a corporate update in response to COVID-19.

Revance Therapeutics reported fourth-quarter financial results, with key highlights including the FDA's acceptance of the BLA for DAXI in glabellar lines and an exclusive U.S. distribution agreement for TEOXANE dermal fillers. The company's cash, cash equivalents, and short-term investments totaled $290.1 million as of December 31, 2019.